证券代码：603567 证券简称：珍宝岛 公告编号：临 2025-056 黑龙江珍宝岛药业股份有限公司 关于部分限制性股票回购注销的实施公告 | 回购数量（股） | 注销数量（股） | | | 注销日期 | | | | --- | --- | --- | --- | --- | --- | --- | | 144,094 | 144,094 | 2025 | 年 | 7 月 | 29 | 日 | 一、本次限制性股票回购注销的决策与信息披露 1、公司于 2025 年 3 月 25 日召开第五届董事会第十九次会议和第五届监事 会第十六次会议，分别审议并通过《关于公司回购注销部分离职激励对象已获授 但尚未解除限售的限制性股票的议案》，同意公司回购注销本激励计划中 3 名离 职人员已获授但尚未解除限售的 144,094 股限制性股票，北京市兰台律师事务所 关于本次回购注销事项出具了法律意见书，具体内容详见公司于 2025 年 3 月 26 日在上海证券交易所网站 www.sse.com.cn 披露的相关公告。 2、公司已根据相关法律规定就以上回购注销部分限制性股票事项履行通知 债权人程序，具体内容详见公司于 2025 ...

法律意见书 黑龙江珍宝岛药业股份有限公司 2023 年限制性股票激励计划 部分限制性股票回购注销实施的 法律意见书 地址：北京市朝阳区曙光西里甲1号第三置业B座29层 电话：（8610）52287799 传真：（8610）58220039 邮编：100028 网址：www.lantai.cn 二〇二五年七月 北京市兰台律师事务所 关于 北京市兰台律师事务所 关于黑龙江珍宝岛药业股份有限公司 2023 年限制性股票激励计划 部分限制性股票回购注销实施的 法律意见书 兰 台 意 字 （ 2025） 第 3874 号 致 ： 黑 龙 江 珍 宝 岛 药 业 股 份 有 限 公 司 北京市兰台律师事务所（以下简称"兰台"或"本所"）接受黑龙江珍宝岛 药业股份有限公司（以下简称"公司"或"珍宝岛"）的委托，作为公司 2023 年限制性股票激励计划（以下简称"本次股权激励计划"）的特聘专项法律顾问。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）、中国证券监督管理委员会 （以下简称"中国证监会"）《上市公司股权激励管理办法》（以下简称"《管 理办法》" ...

Group 1 - The company has provided a guarantee of up to RMB 200 million for its subsidiary Anhui Jiuzhou Fangyuan Pharmaceutical Co., Ltd. to meet its bank financing needs [1][2] - The guarantee is structured as a joint liability guarantee with a term of 12 months, and there is a counter-guarantee in place [1][2] - The board of directors approved the guarantee proposal with a majority vote, and it was subsequently ratified by the shareholders' meeting [1][2] Group 2 - A counter-guarantee agreement has been signed with other shareholders of Anhui Jiuzhou Fangyuan, who will use their personal assets to cover the guarantee provided by the company [2] - The counter-guarantee covers all loan principal and interest, including penalties and related costs incurred by the company [2] - The necessity and reasonableness of the guarantee are justified by the stable operational status and good credit record of the subsidiary, ensuring that the risks are manageable and do not harm the company's interests [3]

一、担保的基本情况 为满足黑龙江珍宝岛药业股份有限公司（以下简称"公司"或"珍宝岛"） 参股子公司安徽九洲方圆制药有限公司（以下简称"安徽九洲方圆"）的银行融 资需要，公司于 2025 年 7 月 16 日与中国农业银行亳州谯城支行签订《最高额保 证合同》，为参股子公司安徽九洲方圆向其申请借款提供担保，担保本金最高金 额为人民币 2.00 亿元，担保方式为连带责任保证，保证期限为 12 个月。本次担 保存在反担保。 二、内部决策程序 证券代码：603567 证券简称：珍宝岛 公告编号：临2025-055 公司于 2025 年 6 月 15 日召开第五届董事会第二十四次会议，审议并通过了 《关于为参股子公司提供担保的议案》，该议案已经全体董事的过半数董事审议 通过以及出席董事会会议的三分之二以上董事审议通过，董事会同意提请公司股 东大会授权公司法定代表人处理在核定担保额度内的担保事项并签署相关协议。 黑龙江珍宝岛药业股份有限公司 公司于 2025 年 6 月 25 日召开 2024 年年度股东大会会议，审议并通过了《关 于为参股子公司提供担保的议案》，同意公司对参股子公司提供担保金额为 2.00 亿元的担保。 ...

Core Viewpoint - On July 21, a total of 23 listed companies had their restricted shares unlocked, with a total market value of approximately 5.36 billion yuan [1] Summary by Category Restricted Share Unlocking - The specific details of the restricted share unlocking include: - Shandong High Energy (000803): 1.2772 million shares from equity incentive - Yueyang Xingchang (000819): 2.1525 million shares from equity incentive - Zhangyu A (000869): 2.0357 million shares from equity incentive - Sheneng Co., Ltd. (600642): 9.7161 million shares from equity incentive - Batian Co., Ltd. (002170): 1.2 million shares from equity incentive - Wanma Co., Ltd. (002276): 2.6112 million shares from equity incentive - Chuanfa Longmang (002312): 12.5 million shares from A-share issuance - Chengda Pharmaceutical (301201): 6.15594 million shares with extended lock-up period - Maoshuo Power (002660): 8.22983 million shares from A-share issuance - Laobaixing (603883): 193.6 thousand shares from equity incentive - Zhenbaodao (603567): 726.9 thousand shares from equity incentive - Lifang Pharmaceutical (003020): 234 thousand shares from equity incentive - Triangle Defense (300775): 110.4 thousand shares from equity incentive - Yidao Information (001314): 46.26 thousand shares from equity incentive - Honghe Technology (603256): 252.65 thousand shares from equity incentive - Guomao Co., Ltd. (603915): 165.8 thousand shares from equity incentive - Arrow Home (001322): 135.28 thousand shares from equity incentive - Hongying Intelligent (001266): 18 thousand shares from equity incentive - Kangpeng Technology (688602): 4.6189 million shares - Juyi Technology (688162): 108.1 thousand shares - Xidiwei (688173): 15.4 million shares - Aike Optoelectronics (688610): 68 thousand shares - Hangcai Co., Ltd. (688563): 180 thousand shares [1]

Core Viewpoint - The company, Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd., has announced a guarantee for its associate company, Anhui Jiuzhou Fangyuan Pharmaceutical Co., Ltd., amounting to RMB 200 million to support its bank financing needs [1][2]. Summary by Sections Guarantee Overview - The guarantee is provided to Anhui Jiuzhou Fangyuan for a maximum amount of RMB 200 million, with a guarantee period of 12 months [1][4]. - The guarantee is structured as a joint liability guarantee, and there is a counter-guarantee from other shareholders of Anhui Jiuzhou Fangyuan [2][4]. Internal Decision-Making Process - The company's board of directors approved the guarantee proposal on June 15, 2025, with a majority of directors in favor [2]. - The shareholders' meeting on June 25, 2025, also approved the guarantee amount of RMB 200 million [2]. Basic Information of the Guaranteed Entity - Anhui Jiuzhou Fangyuan is a company in which the company holds a 34.82% stake, with other major shareholders holding significant portions as well [3]. - The company was established on May 7, 2013, and has a registered capital of RMB 324.76 million [3]. Main Content of the Guarantee Agreement - The guarantee covers all debts including principal, interest, penalties, and any costs incurred in enforcing the creditor's rights [4]. - The total amount of external guarantees provided by the company is RMB 1.791 billion, which is 22.96% of the company's latest audited net assets [5]. Necessity and Reasonableness of the Guarantee - The guarantee is deemed necessary to support the operational needs of Anhui Jiuzhou Fangyuan, which has a stable operational status and good credit record [4][5]. - The board believes that the risks associated with the guarantee are controllable and will not harm the interests of the company or its shareholders [5].

黑龙江珍宝岛药业股份有限公司 证券代码：603567 证券简称：珍宝岛 公告编号：临2025-054 为满足参股子公司安徽九洲方圆制药有限公司（以下简称"安徽九洲方圆"） 的银行融资需要，公司于 2025 年 7 月 16 日与中国农业银行亳州谯城支行签订《最 高额保证合同》，为参股子公司安徽九洲方圆向其申请借款提供担保，担保本金 最高金额为人民币 2.00 亿元，担保方式为连带责任保证，保证期限为 12 个月。 本次担保存在反担保。 （二） 内部决策程序 关于为参股子公司提供担保进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | 被担保人名称 | | 安徽九洲方圆制药有限公司 | | | --- | --- | --- | --- | | 本次担保金额 | 20,000 | 万元 | | | 实际为其提供的担保余额 担保对象 | 20,000 | 万元 | | | 是否在前期预计额度内 | 是 | □否 | □不适用：_________ | | 本次担保是否有反担保 | 是 ...

Group 1 - The company expects a net profit attributable to shareholders of approximately -77 million to -66 million yuan for the first half of 2025, indicating a loss compared to the same period last year [1][2] - The expected net profit attributable to shareholders after deducting non-recurring gains and losses is approximately -83 million to -73 million yuan [1][2] - The performance forecast period is from January 1, 2025, to June 30, 2025, and the forecast is based on preliminary calculations by the company's financial department, not yet audited by certified public accountants [1][2] Group 2 - In the same period last year, the total profit was 501.67 million yuan, with a net profit attributable to shareholders of 393.33 million yuan and a net profit of 362.12 million yuan after deducting non-recurring gains and losses [2] - The primary reason for the expected loss is a decrease in product prices, leading to a 57% year-on-year decline in revenue and a 64% year-on-year decline in gross profit [2]

Core Viewpoint - The company, Zhenbaodao (603567.SH), is focusing on a dual-driven strategy of "Modern Traditional Chinese Medicine + Innovative Drugs" to enhance its growth potential and competitiveness in the pharmaceutical industry [1] Group 1: Business Strategy - The company is intensifying its efforts in smart manufacturing of traditional Chinese medicine, innovative drug research and development, and biopharmaceutical layout [1] - The R&D progress of the company's Class 1 innovative traditional Chinese medicine, Qingjiang Weigao Granules, has reached a critical milestone with the successful enrollment of the first subject in the Phase II clinical trial at Changsha Third Hospital [1] Group 2: Product Development - The company’s equity investment in Teruisi ADC innovative drug pipeline is showing substantial progress, with multiple projects advancing to clinical or registration preparation stages [1] - The core product competitiveness and medium to long-term growth potential of the company are expected to be further enhanced [1]

证券代码：603567 证券简称：珍宝岛 公告编号：2025-053 黑龙江珍宝岛药业股份有限公司 2025年半年度业绩预告的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: ●本期业绩预告适用于净利润为负值的情形。 ●黑龙江珍宝岛药业股份有限公司（以下简称"公司"）预计2025年半年度 实现归属于上市公司股东的净利润约为-7,700万元到-6,600万元，与上年同期相 比，将出现亏损。 ●公司预计2025年半年度实现归属于上市公司股东的扣除非经常性损益的净 利润约为-8,300万元到-7,300万元。 一、本期业绩预告情况 （一）业绩预告期间：2025年1月1日至2025年6月30日。 （二）业绩预告情况 1、经财务部门初步测算，公司预计2025年半年度实现归属于上市公司股东 的净利润约为-7,700万元到-6,600万元，与上年同期相比，将出现亏损。 2、公司预计2025年半年度实现归属于上市公司股东的扣除非经常性损益的 净利润约为-8,300万元到-7,300万元。 （三）本期业绩预告为公司根据经营情 ...